KCM
KPTI icon

Kennedy Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Kennedy Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-79,686
Closed -$808K – 674
2024
Q4 		$808K Sell
79,686
-581
-0.7% -$7.03K 0.02% 609
2024
Q3 		$999K Buy
80,267
+481
+0.6% +$5.98K 0.02% 591
2024
Q2 		$1.04M Buy
+79,786
New +$1.32M 0.02% 586
2018
Q2 		– Sell
-6,181
Closed -$1.24M – 767
2018
Q1 		$1.24M Buy
+6,181
New +$1.23M 0.02% 650

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Kennedy Capital Management's KPTI Position: Q1 2025 in Review

Kennedy Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 79,686 shares — an estimated $808K sold.

Kennedy Capital Management first reported a position in KPTI in Q1 2018 and held it in 4 quarters. The position peaked at $1.24M in Q1 2018. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Kennedy Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 79,686 Karyopharm Therapeutics shares in Q1 2025, an estimated $808K.
  • Kennedy Capital Management first reported a position in Karyopharm Therapeutics in Q1 2018 and held it in 4 quarters.
  • Kennedy Capital Management's Karyopharm Therapeutics position peaked at $1.24M in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Kennedy Capital Management's 13F filing for Q1 2025, filed 13 May 2025.